Market Closed -
Deutsche Boerse AG
11:30:35 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.765
EUR
|
-5.56%
|
|
-5.56%
|
-29.17%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
349.6
|
225.2
|
171.1
|
105.5
|
30.78
|
24.79
|
-
|
-
|
Enterprise Value (EV)
1 |
349.6
|
225.2
|
171.1
|
105.5
|
30.78
|
24.79
|
24.79
|
24.79
|
P/E ratio
|
-13.6
x
|
-7.53
x
|
52.9
x
|
-7.02
x
|
-1.09
x
|
-1.07
x
|
-1.78
x
|
-2.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.3
x
|
25.7
x
|
5.47
x
|
27.2
x
|
19.8
x
|
4.96
x
|
3.2
x
|
2.95
x
|
EV / Revenue
|
15.3
x
|
25.7
x
|
5.47
x
|
27.2
x
|
19.8
x
|
4.96
x
|
3.2
x
|
2.95
x
|
EV / EBITDA
|
-1,39,50,647
x
|
-80,22,004
x
|
3,77,57,913
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-15.1
x
|
-8.77
x
|
-21.8
x
|
-10.9
x
|
-
|
-1.36
x
|
-1.42
x
|
-1.61
x
|
FCF Yield
|
-6.61%
|
-11.4%
|
-4.58%
|
-9.15%
|
-
|
-73.4%
|
-70.6%
|
-62.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,387
|
23,001
|
23,119
|
23,129
|
27,858
|
27,858
|
-
|
-
|
Reference price
2 |
17.15
|
9.790
|
7.400
|
4.560
|
1.105
|
0.8900
|
0.8900
|
0.8900
|
Announcement Date
|
24/03/20
|
04/03/21
|
30/03/22
|
10/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22.9
|
8.771
|
31.27
|
3.883
|
1.554
|
4.998
|
7.74
|
8.4
|
EBITDA
|
-25.06
|
-28.07
|
4.531
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-25.95
|
-30.23
|
2.964
|
-16.24
|
-29.3
|
-24.38
|
-17.26
|
-15.6
|
Operating Margin
|
-113.3%
|
-344.69%
|
9.48%
|
-418.34%
|
-1,885.78%
|
-487.8%
|
-223.02%
|
-185.71%
|
Earnings before Tax (EBT)
1 |
-24.58
|
-29.29
|
3.221
|
-14.92
|
-27.24
|
-23.22
|
-16.05
|
-14.6
|
Net income
1 |
-24.61
|
-29.29
|
3.221
|
-14.92
|
-27.24
|
-23.22
|
-16.05
|
-14.6
|
Net margin
|
-107.44%
|
-333.94%
|
10.3%
|
-384.32%
|
-1,752.77%
|
-464.63%
|
-207.38%
|
-173.81%
|
EPS
2 |
-1.260
|
-1.300
|
0.1400
|
-0.6500
|
-1.010
|
-0.8300
|
-0.5000
|
-0.3400
|
Free Cash Flow
1 |
-23.1
|
-25.69
|
-7.834
|
-9.655
|
-
|
-18.2
|
-17.5
|
-15.4
|
FCF margin
|
-100.84%
|
-292.9%
|
-25.05%
|
-248.65%
|
-
|
-364.15%
|
-226.11%
|
-183.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/20
|
04/03/21
|
30/03/22
|
10/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.336
|
20.81
|
0.003
|
3.518
|
0.261
|
0.1
|
0.758
|
0.594
|
0.213
|
0.447
|
0.466
|
1.607
|
1.177
|
1.748
|
1.3
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
1.272
|
13.96
|
-5.95
|
-0.463
|
-3.625
|
-6.205
|
-10.6
|
-6.527
|
-6.307
|
-5.407
|
-6.712
|
-5.643
|
-6.223
|
-5.802
|
-
|
Operating Margin
|
95.21%
|
67.08%
|
-1,98,333.33%
|
-13.16%
|
-1,388.89%
|
-6,205%
|
-1,399.08%
|
-1,098.82%
|
-2,961.03%
|
-1,209.62%
|
-1,440.34%
|
-351.15%
|
-528.72%
|
-331.92%
|
-
|
Earnings before Tax (EBT)
1 |
1.286
|
14.03
|
-5.597
|
-0.134
|
-3.407
|
-5.785
|
-10.26
|
-5.97
|
-5.711
|
-4.836
|
-6.344
|
-5.313
|
-5.983
|
-5.582
|
-
|
Net income
1 |
1.286
|
14.03
|
-5.597
|
-0.134
|
-3.407
|
-5.785
|
-10.26
|
-5.97
|
-5.711
|
-4.836
|
-6.344
|
-5.313
|
-5.983
|
-5.582
|
-
|
Net margin
|
96.26%
|
67.43%
|
-1,86,566.67%
|
-3.81%
|
-1,305.36%
|
-5,785%
|
-1,353.96%
|
-1,005.05%
|
-2,681.22%
|
-1,081.88%
|
-1,361.37%
|
-330.62%
|
-508.33%
|
-319.34%
|
-
|
EPS
2 |
0.0500
|
0.6100
|
-0.2400
|
-0.0100
|
-0.1500
|
-0.2500
|
-0.4100
|
-0.2200
|
-0.2100
|
-0.1700
|
-0.2300
|
-0.1900
|
-0.2100
|
-0.2000
|
-0.2100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
30/03/22
|
13/05/22
|
04/08/22
|
10/11/22
|
10/03/23
|
12/05/23
|
10/08/23
|
09/11/23
|
13/03/24
|
20/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-23.1
|
-25.7
|
-7.83
|
-9.66
|
-
|
-18.2
|
-17.5
|
-15.4
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.6
|
0.45
|
0.14
|
0.17
|
-
|
0.1
|
0.1
|
0.1
|
Capex / Sales
|
2.61%
|
5.12%
|
0.46%
|
4.4%
|
-
|
2%
|
1.29%
|
1.19%
|
Announcement Date
|
24/03/20
|
04/03/21
|
30/03/22
|
10/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
0.89
USD Average target price
6
USD Spread / Average Target +574.16% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|